Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020112672 - BIOMARKERS PREDICTIVE OF CANCER CELL RESPONSE TO ML329 OR A DERIVATIVE THEREOF

Publication Number WO/2020/112672
Publication Date 04.06.2020
International Application No. PCT/US2019/063072
International Filing Date 25.11.2019
IPC
C07C 311/17 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
311Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
16having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
17to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
A61K 31/4184 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
41641,3-Diazoles
4184condensed with carbocyclic rings, e.g. benzimidazoles
CPC
A61K 31/4184
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
41641,3-Diazoles
4184condensed with carbocyclic rings, e.g. benzimidazoles
C07C 311/17
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
311Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
16having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
17to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
Applicants
  • DANA-FARBER CANCER INSTITUTE, INC. [US]/[US]
  • THE GENERAL HOSPITAL CORPORATION [US]/[US]
  • UNIVERSITY OF KANSAS [US]/[US]
Inventors
  • HAQ, Rizwan
  • FISHER, David
  • SCHOENEN, Frank
Agents
  • SMITH, Deann, F.
  • CAI, Mi
  • AKHIEZER, Alexander
  • ABELLEIRA, Susan, M.
  • BLOUNT, Jennifer, V.
Priority Data
62/771,42926.11.2018US
62/775,18104.12.2018US
62/935,38614.11.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) BIOMARKERS PREDICTIVE OF CANCER CELL RESPONSE TO ML329 OR A DERIVATIVE THEREOF
(FR) BIOMARQUEURS PRÉDICTIFS D'UNE RÉPONSE DE CELLULE CANCÉREUSE AU TRAITEMENT PAR ML329 OU UN DÉRIVÉ DE CELUI-CI
Abstract
(EN)
The present invention is based in part on the identification of biomarkers, including NQOl, NRF2 and KEAP1, predictive of cancer cell responsiveness to treatment with ML 329 or a derivative thereof.
(FR)
La présente invention est basée en partie sur l'identification de biomarqueurs, comprenant NQOl, NRF2 et KEAP1, prédictifs de la réactivité des cellules cancéreuses au traitement par ML 329 ou un dérivé de celui-ci.
Latest bibliographic data on file with the International Bureau